Publication | Closed Access

Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma

Lymphoid NeoplasiaMedicineSingle-agent GemcitabineClinical TrialsChemotherapy-refractory HodgkinPharmacotherapyCancer TreatmentOncologyRadiation OncologyChemotherapyHealth Sciences